Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain
Biotech
Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset
Novartis discontinued the study after an interim analysis found an “insufficient effect on pain relief,” a spokesperson said.
Gabrielle Masson
Apr 16, 2025 2:55pm
Novo Holdings-backed SiteOne charges up with $100M financing
Dec 18, 2024 7:00am
Lundbeck slashes value of $250M Abide buyout after pain setback
Oct 24, 2024 7:20am
Polyrizon pays $3M for license to SciSparc's CB2R agonist
Aug 19, 2024 5:27am
The neural circuits behind the placebo effect
Jul 24, 2024 9:02am
AI may influence whether you can get pain medication
Aug 31, 2023 9:25am